You are here: Industry Insights > INOVIO

News List

INOVIO, Advaccine Expand COVID Vax Alliance contractpharma
June 09, 2021
INOVIO has expanded its partnership with Advaccine Biopharmaceuticals Suzhou Co., Ltd. to jointly conduct a global Phase 3 segment of the ongoing Phase 2/3 trial called INNOVATE (INOVIO INO-4800 Vaccine Trial for Efficacy).
INOVIO's Pan-COVID-19 Vaccine Candidate (INO-4802) Induces Broad Immunity Against Major Viral Variants in Preclinical Studies prnewswire
May 13, 2021
INOVIO, a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, announced that its next-generation Pan-COVID-19 vaccine candidate ...
Inovio reports positive data from Phase II Covid-19 DNA vaccine trial pharmaceutical-technology
May 12, 2021
The Inovio vaccine Phase II trial assessed the safety, tolerability and immunogenicity of two doses of INO-4800 to detect optimal dose(s) for age groups, namely 18 to 50 years and 51 years and above, for the Phase III efficacy analysis.
INOVIO’s DNA COVID Vax Achieves Positive Results contractpharma
May 11, 2021
Phase 2 clinical trial shows INO-4800 was generally safe, well-tolerated and immunogenic in all studied age groups.
INOVIO Planning for ex-US Global Phase 3 Trial for INO-4800 prnasia
April 25, 2021
INOVIO, a biotechnology company focused on bringing to market precisely designed DNA medicines to treat and protect people from infectious diseases, cancer, and HPV-associated diseases, announced that it is planning for a predominantly ex-U.S. Phase 3 ...
Inovio may move COVID-19 vaccine trial overseas after funding from US ends expresspharma
April 25, 2021
Inovio said, depending on the results of its mid-stage trial, it would run the late-stage study for its vaccine candidate, INO-4800, with partners such as China’s Advaccine and the International Vaccine Institute.
INO-4800 COVID-19 vaccine provides cross-reactive immune responses against variants europeanpharmaceuticalreview
April 20, 2021
Antibodies induced by the investigational DNA vaccine candidate, INO-4800, were found to be able to neutralise three SARS-CoV-2 emerging variants of concern.
Inovio’s Covid-19 vaccine induces immune responses against variants pharmaceutical-technology
April 19, 2021
Inovio has reported that results from a study of its DNA Covid-19 vaccine candidate INO-4800 showed it induced a robust T cell response in humans against all spike protein variants of concern.
INOVIO Announces Positive Results from REVEAL 1, a Phase 3 Pivotal Trial Evaluating VGX-3100, its DNA-based HPV Immunotherapy for the Treatment of High-grade Precancerous Cervical Dysplasia Caused by prnasia
March 02, 2021
INOVIO today announced it met primary and secondary endpoints among all evaluable subjects for the REVEAL 1 trial.
Patient dosed with first Lassa fever vaccine to reach human trials europeanpharmaceuticalreview
February 25, 2021
The first trial participant has been given INO-4500 in Ghana – INO-4500 is a DNA vaccine candidate being developed to protect against Lassa fever.

Previous page 1 2 3 4 5 Next page